Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics cuts 46% of workforce, advances SION-451 dual combination to Phase 2a

Mixed Impact 4 of 5 restructuring Written later

Sionna Therapeutics said its Board approved a restructuring on September 9, 2026, that cuts about 46% of its workforce and winds down the SION-719 add-on program, with aggregate charges currently estimated at about $6.4 million. The company said the changes are meant to focus resources on the SION-451 and SION-2222 dual combination and extend its cash runway into the second half of 2029. Its Chief Business Officer's employment is ending, and the company is repricing employee stock options.

Key points

  • Restructuring charges are estimated at about $6.4 million, including $5.3 million in employee severance and other post-employment benefits, $0.7 million in SION-719 contract close-out costs and $0.4 million in stock-based compensation.
  • Workforce reduction and vendor wind-down are expected to be substantially complete by the end of the third quarter of 2026.
  • The company had about $268.3 million in cash, cash equivalents and marketable securities at the end of Q2 2026, and expects its runway to extend into the second half of 2029.
  • Chief Business Officer Caroline Stark Beer's employment ends September 15, 2026; option repricing takes effect September 17, 2026.

The filing

CompanySionna Therapeutics, Inc. (SION)
Form8-K, current report
Filed with the SECSep 14, 2026, 4:10 PM ET
Accession number0001193125-26-390577

Items reported: 2.05 Exit / Restructuring Costs5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.